Galderma will present new data from across its portfolio, including findings from the RELAX and EXPRESSION studies on Relfydess® (RelabotulinumtoxinA) highlighting its rapid onse ...
In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback